Skip to main content

Increasing Body Mass Index Tied to 18 Site-Specific Cancers in Men

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 13, 2023.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Dec. 13, 2023 -- Increasing body mass index (BMI) at age 18 years is associated with development of subsequent site-specific cancers in men, according to a study published online Nov. 6 in Obesity.

Aron Onerup, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined BMI at age 18 years and incident site-specific cancer (malignant melanoma; leukemia; myeloma; Hodgkin lymphoma; non-Hodgkin lymphoma; and cancer in the lungs, head and neck, central nervous system, thyroid, esophagus, stomach, pancreas, liver and gallbladder, colon, rectum, kidney, and bladder) to estimate population attributable fractions due to BMI based on projected obesity prevalence. The analysis included 1.5 million men.

The researchers found that 78,217 men subsequently developed cancer during a mean 31 years of follow-up. There was a linear association between BMI and the risk for developing all 18 site-specific cancers assessed. In some instances, there was an association even with BMI levels usually defined as normal (20 to 25 kg/m2). For prostate cancer, there was an inverse association observed, with higher BMI associated with lower risk. Gastrointestinal cancers had the highest hazard ratios and population attributable fractions.

"If current obesity trends continue, our findings provide additional support for rapid action to stem the course of the obesity epidemic and, with a large prevalence of youth overweight and obesity already in existence, to prepare the health care system for a steeply increasing number of cancer cases,” the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight

TUESDAY, May 14, 2024 -- Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week...

Metabolic Syndrome, Obesity Independently Linked to Breast Cancer

MONDAY, May 13, 2024 -- Metabolic syndrome (MetS) and obesity have independent and distinct associations with breast cancer subtypes and mortality, according to a study published...

Lower Prevalence of Employment Seen for Survivors of Childhood Cancer

FRIDAY, May 10, 2024 -- Adult survivors of childhood cancer have declines in employment and increases in health-related unemployment compared with the general population...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.